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Thymidylate synthase (TS) is the rate-limiting enzyme essential
for the de novo synthesis of the pyrimidine nucleotide thymidyl-
ate. Because thymine bases are only found in DNA, specific
inhibitors of thymidylate synthase may be expected to induce an
antiproliferative effect which is uncomplicated by effects at other
biochemical loci, i.e. protein synthesis. It might be expected that
such an agent would be relatively free from side-effects on non-
proliferating tissues.
A number of drugs which are known to inhibit thymidylate
synthase have been synthesized and used clinically. The most
widely used is 5-fluorouracil (5-FU) (Valeriote and Santelli, 1984), a
substrate analogue which is rapidly metabolized within the cell to a
number of fluorinated nucleotide moieties. One of these metabo-
lites, 5-fluorodeoxyuridine monophosphate (5-FdUMP) is a potent
inhibitor of thymidylate synthase (Santi et al, 1974). However, 5-FU
has multiple biochemical sites of action because other nucleotide
metabolites may be incorporated into DNA or RNA (Pinedo and
Peters, 1988).
Therefore, a selective inhibitor of thymidylate synthase may be
more effective than 5-FU. In particular, such an inhibitor would be
more likely to have a unique locus of action, would not be incor-
porated into nucleic acids and might not be susceptible to catabolic
degradation. A number of folate-based thymidylate synthase
inhibitors have been synthesized and entered clinical trial. The
first of these, CB 3717, displayed promising clinical activity
(Calvert et al, 1986, 1987; Bassendine et al, 1987; Cantwell et al,
1988), but its development was abandoned because of sporadic
and unpredictable nephrotoxicity and myelotoxicity. A successor
to CB 3717, raltitrexed (Tomudex™) (Jackman et al, 1991), has
been shown to be non-nephrotoxic (Jodrell et al, 1991) and is
currently in use clinically in the treatment of patients with
metastatic colorectal cancer.
Both CB 3717 and Tomudex™ are ‘classical antifolates’ in that
they enter the cell via the ‘reduced folate carrier’ protein and contain
a terminal glutamate moiety which renders them substrates for the
folyl-polyglutamate synthetase enzyme (FPGS). Metabolism to
intracellular polyglutamate forms by FPGS greatly increases the
potency of these drugs and also leads to intracellular retention.
However, variations in the rate of formation and retention of these
polyglutamates may well be responsible for the variable toxicity
observed with these drugs. Further, the possession of a glutamate
residue renders the drug hydrophilic and precludes its entry into
tissues which do not possess a folate transport system. In particular,
classical antifolates penetrate the central nervous system poorly
such that intrathecal or high-dose administration is necessary.
Nolatrexed dihydrochloride (Thymitaq™, AG337) (Jackson et
al, 1992; US Patent Application, 1992) is a lipophilic inhibitor of
thymidylate synthase which should circumvent the problems with
classical antifolates outlined above. It was designed by Agouron
Pharmaceuticals using X-ray crystallographic techniques and
molecular modelling (Appelt et al, 1991), and is the first potent
lipophilic thymidylate synthase inhibitor to be proposed for
clinical study.
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Summary 2-Amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride (nolatrexed dihydrochloride, Thymitaq, AG337),
a specific inhibitor of thymidylate synthase, was developed using protein structure-based drug design. Intravenously administered nolatrexed
is active clinically. As oral bioavailability is high (70–100%), nolatrexed was administered orally, 6 hourly for 10 days, at 3-week intervals, and
dose escalated from 80 to 572 mg m–2 day–1 in 23 patients. Common toxicity criteria (CTC) grade 3 toxicities included nausea, vomiting,
stomatitis and liver function test (LFT) abnormalities. Thrombocytopenia (grade 1 or 2) occurred at doses ³ 318 mg m–2 day–1 and neutropenia
(grade 2) at 429 and 572 mg m–2 day–1. An erythematous maculopapular rash occurred at dosages ³ 318 mg m–2 day–1 (7 out of 19 patients).
LFT abnormalities occurred in two out of six patients (grade 3 or 4 bilirubin and grade 3 alanine transaminase) at 572 mg m–2 day–1.
Nolatrexed plasma concentrations 1 h after dosing were 6–16 mg ml–1, and trough 3–8 mg ml–1, at 572 mg m–2 day–1. Inhibition of thymidylate
synthase was demonstrated by elevation of plasma deoxyuridine. Six-hourly oral nolatrexed for 10 days was associated with antiproliferative
effects, but nausea and vomiting was dose limiting at 572 mg m–2 day–1. Nine patients were treated at 429 mg m–2 day–1; three out of nine
experienced grade 3 nausea, but 17 out of 22 treatment courses were completed (with the co-administration of prophylactic antiemetics) and
this dose level could be considered for phase II testing.
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General Hospital, Edinburgh EH4 2XU, UKNolatrexed entered clinical trial at Newcastle General Hospital
under the auspices of the CRC Phase I/II Clinical Trials
Committee in November 1992. Using a continuous 24-h infusion,
the maximum dose administered was 1073 mg m–2 and no
systemic toxicity was encountered, but CTC grade 2 local toxicity
(phlebitis) was observed (Rafi et al, 1995). This local toxicity
necessitated the use of central venous catheters (Hickman lines).
Preclinical data had suggested that nolatrexed would be more
effective when given as a prolonged infusion and, therefore,
studies to investigate the administration of nolatrexed when given
as 5- and 10-day infusions have also been performed (Rafi et al,
1998; Creaven et al, 1998).
Prolonged intravenous administration requires either prolonged
hospital admission or the use of ambulatory infusion devices.
However, nolatrexed also demonstrated significant oral bioavail-
ability in two species. In rats, fasted before treatment, the oral
bioavailability of nolatrexed at doses of 20, 40 and 80 mg kg–1 was
53%, 50% and 30% respectively. These doses equate to doses of
120, 240 and 480 mg m–2. In dogs (fasted overnight), nolatrexed
delivered in 5% dextrose by gavage was > 90% bioavailable. The
bioavailability of the proposed clinical formulation (nolatrexed in
capsules with microcrystalline cellulose and crospovidone) was
70% and 107% in one dog and 87% in a second dog, when dosing
was preceded and followed by water gavage. In patient studies of
5-day oral administration, bioavailability was high (70–100%)
(Rafi et al, 1996). To study the feasibility and effects of more
prolonged oral administration, a phase I study of 10-day adminis-
tration was undertaken.
The objectives of the study were: (a) to determine the maximum
tolerated dose of nolatrexed when given orally to cancer patients
in divided doses over 10 days; (b) to establish the dose-limiting
and other toxicities associated with the repeated oral administra-
tion of nolatrexed; (c) to study the pharmacokinetics of nolatrexed
in individual patients using a limited number of plasma samples;
(d) to determine whether the plasma concentrations achieved
cause inhibition of the target enzyme, thymidylate synthase; (e) to
document any anti-tumour effects related to treatment with
nolatrexed; and (f) to propose a suitable dose for the phase II
evaluation of activity.
PATIENTS AND METHODS
This was a non-randomized ‘phase I’ study with dose escalation.
The methodology used followed the guidelines set out in the CRC
Phase I/II Committee Operation manual. The study was conducted
in accordance with the Declaration of Helsinki and ethical approval
was granted by the Lothian Medicine and Clinical Oncology
Research Ethics Sub-Committee (reference: 1702/94/4/70).
The following criteria were used to assess eligibility: a histologi-
cally proven diagnosis of a malignant disease for which no satisfac-
tory treatment existed or against which established treatments had
failed; patients had to be capable of understanding the nature of the
trial and must have been capable of giving written informed consent;
WHO performance status of 0–2. Patients had not received previous
chemotherapy for 4 weeks and had recovered fully from previous
myelosuppressive chemotherapy. No radiotherapy, nitrosoureas or
mitomycin C were allowed within the preceding 6 weeks. Evidence
of adequate haematological reserve and renal and hepatic function
were required [haemaglobin (Hb) ³ 10 g dl–1, white blood cells
(WBC)  ³ 4.0 ´ 1091–1, platelets ³ 100 ´ 109 l–1], normal renal func-
tion (calculated creatinine clearance ³ 60 ml min–1) and bilirubin.
Other liver function tests (e.g. alkaline phosphatase, alanine trans-
aminase, g-glutamyl transpeptidase) were required to be less than
twice the upper limit of normal, unless clearly due to the presence of
tumour. A life expectancy of at least 3 months was expected and all
patients were ³ 18 years old.
Patients were excluded in the event of: brain metastases or
primary brain tumours which precluded obtaining informed
consent or were likely to require treatment with radiotherapy,
severe pre-existing medical conditions, evidence of bone marrow
involvement with tumour, concurrent use of other experimental
agents or anti-cancer therapy, haematological malignancies, the
need for concurrent administration of trimethoprim, antiepileptics,
cotrimoxazole or pyrimethamine. Other exclusion criteria
included women who were pregnant or breast feeding (patients
utilized medically approved contraceptive precautions, if neces-
sary, during the trial and for 4 weeks afterwards), patients who had
received very extensive previous therapy in whom bone marrow
function was likely to be compromised, patients receiving folate-
containing vitamin supplements.
Drug administration and dose escalation
Drug was supplied in size 4 and size 2 capsules containing 20 mg
and 80 mg of nolatrexed (as free base) respectively. The inactive
contents of the capsules comprised microcrystalline cellulose,
crospovidone (5% weight of filled capsule) and magnesium
stearate (0.5% weight of filled capsule). The capsules were stored
in a cool, dry place (not refrigerated). Doses were to be adminis-
tered at least 30 min before or 2 h after food. All nolatrexed doses
and concentrations are expressed as free base.
The planned starting dose of nolatrexed was 40 mg m–2 adminis-
tered every 6 h; i.e. total daily dose = 159 mg m–2 and total dose =
1590 mg m–2. Total daily dose was calculated and divided by four
to give the 6-hourly dose. The 6-hourly dose was rounded up or
down to the nearest 20 mg in view of the available capsule sizes.
Ten days of nolatrexed constituted one course of treatment.
Treatment courses were repeated every 21 days, provided any
drug-related non-haematological toxicities had resolved and WBC
³ 3.0 ´ 109 l–1 and platelets ³ 100 ´ 109 l–1.
Dose escalation was guided by the incidence of drug-related
toxicity, and in the absence of drug-related toxicity the dose was
doubled. Doses could be escalated within individual patients if no
drug-related toxicities were observed at the previous dose level.
Three patients were entered per dose level if no drug-related toxic-
ities ³ common toxicity criteria (CTC) grade 2 (except nausea and
vomiting) were observed. Five patients per dose level were to be
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Table 1 Number of patients treated at each dose level
Dose level No. of patients No. of cycles No. of incomplete
cycles
(reason given)
80 mg m–2 day–1 1 2 1 (PD)
159 mg m–2 day–1 3 7 3 (PD)
318 mg m–2 day–1 5a 16 2 (toxicity)
429 mg m–2 day–1 9a 22 5 (4 toxicity
1 UT1)
572 mg m–2 day–1 6 8 5 (DLT defined)
aOne patient had two cycles at 318 mg m–2 day–1 and three cycles at
429 mg m–2 day–1.entered if ³ CTC grade 2 toxicities were observed. Additional
patients were to be entered at the recommended phase II dose.
The maximum tolerated dose was defined as the dose associated
with an incidence of dose-limiting toxicity (DLT) in three or more
of the five patients per dose level. In this study, a DLT was defined
as grade III or IV myelosuppression of more than 4 days duration
and/or associated with neutropenic sepsis. Nausea (and/or
vomiting) was considered dose limiting if it was uncontrolled by
antiemetic therapy and/or limited the completion of the prescribed
course of treatment. For other non-haematological toxicities, DLT
was defined as the incidence of grade III or IV toxicity (excluding
alopecia).
Before treatment and before each course, patients underwent
clinical examination, full blood count, urea and electrolytes, liver
function tests, calculated creatinine clearance (or chromium EDTA
clearance if borderline renal function). During the first course of
treatment, full blood count, urea and electrolytes and liver function
tests were performed twice weekly and weekly thereafter.
Pharmacokinetic and pharmacodynamic sampling and
assessment
Limited pharmacokinetic sampling was performed during course
1. Heparinized blood samples (3 ml) were collected, for subse-
quent plasma drug assay, before drug administration, and 30–
60 min after dosing on days 1, 4, 8 and 10. Plasma and deoxyuri-
dine (dUrd) concentrations were also assessed during course 1 on
days 1 (pretreatment) and 10. The concentration of nolatrexed was
determined in each plasma sample using a high-performance
liquid chromatography (HPLC) method with UV quantification
and a semiautomated method was used for the determination of
dUrd concentrations in plasma, both of which have been described
previously (Rafi et al, 1995).
Patients with assessable disease had such clinical measurements
and scans performed as were necessary to document the status of
their disease. Clinical measurements were performed within the
week before the patient going on study, and scans were performed
within the month before the patient going on study. Assessable
disease was reassessed after three cycles of treatment, unless there
was clinical/biochemical evidence of disease progression.
Treatment was continued until there was evidence of disease
progression or unacceptable toxicity.
RESULTS
Patient characteristics and toxicities
Twenty-three patients were entered into the study (16 men and
seven women). The median age was 57 (range 44–70). Median
performance status was 1 (range 0–2). Colorectal cancer was the
most common tumour type (12 patients) and other tumour types
were lung [non-small-cell lung cancer (NSCLC); four patients]
gastric (two); mesothelioma (one); renal (one); head and neck
(squamous) (one); unknown primary (adenocarcinoma) (two). The
majority of patients had had prior surgery (20) and chemotherapy
(17). Seven patients had received prior radiotherapy and one
patient endocrine treatment.
In view of concerns regarding the potential schedule depen-
dency of toxicities related to other antimetabolites, one patient was
treated at a preliminary dose level of 80 mg m–2 day–1. This patient
had no evidence of drug-related antiproliferative toxicities, but
subsequently developed progressive disease with bowel obstruc-
tion leading to nausea and vomiting. Therefore, three patients were
accrued to the planned start dose, 159 mg m–2 day–1. The number
of patients and courses at each of five dose levels is shown in Table
1. CTC grade III nausea and vomiting, which was probably or
definitely related to nolatrexed and was associated with failure to
complete the prescribed course of treatment, was encountered at
318 mg m–2 day–1 (Table 2A). This dose level was expanded to five
patients and regular oral antiemetic prophylaxis (domperidone
20 mg every 6 h) was introduced. After completion of this dose
level, three patients were entered at 429 mg m–2 day–1 and these
patients were treated successfully with the co-administration of
domperidone, as above.
At a daily dose of 572 mg m–2 day–1 (143 mg m–2, every 6 h),
nausea and vomiting became dose limiting, despite regular
domperidone. All six patients entered developed persistent grade
III nausea and five out of eight cycles were incomplete. This was
felt to represent the dose-limiting toxicity and the maximum toler-
ated dose appeared to have been defined. In patients who ‘failed’
despite regular domperidone, oral ondansetron was used, and, in
two patients, oral ondansetron (4–8 mg twice daily) was used as
antiemetic prophylaxis. One patient was treated with a combina-
tion of oral ondansetron and dexamethasone (4 mg twice daily),
but became agitated and discontinued therapy. In addition to
nausea, two out of six patients developed grade III stomatitis at
this dose level.
Therefore, the 429 mg m–2 day–1 dose level was expanded to
gain additional experience at what was likely to represent the
recommended phase II dose. Grade 3 nausea was noted in three out
of nine patients and 5 out of 22 cycles were incomplete. Grade 2
stomatitis was encountered in two patients at 429 mg m–2 day–1,
but grade 3 stomatitis was not reported at this dose level.
Myelosuppression (thrombocytopenia and/or neutropenia) was
recorded at daily doses ³ 318 mg m–2. This did not exceed CTC
grade 2 in any patient. At the maximum dose tested (572 mg m–2
day–1), two out of six patients experienced grade 2 neutropenia and
one out of six experienced grade 2 thrombocytopenia.
A skin rash was noted in eight patients and appeared to be most
prominent in sun-exposed areas. It was generally mild and self
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Table 2 Toxicities possibly or probably related to nolatrexed
A Nausea
Daily dose (mg m–2) Number of patients at each CTC grade
0123 4
80 1
159 1 2
318 1 1 1 2
429 1 3 2 3
572 6
B Bilirubin
Daily dose (mg m–2) Number of patients at each CTC grade
0123 4
80 1
159 2 1
318 3 2
429 8 1
572 4 1 1limiting, and therefore biopsies were not performed, although one
patient treated at 572 mg m–2 day–1 was treated using dexamethasone
and chlorpheniramine. Five additional patients also commented on
increased sensitivity to sunlight, but no apparent rash.
Elevation of serum bilirubin was noted in nine patients (Table 2
B), with grade 3 or 4 toxicity occurring in 5 out of 20 patients
treated at doses ³ 318 mg m–2 day–1. These abnormalities were also
associated with rises in serum alanine transaminase (ALT) with
two out of six patients experiencing grade 3 toxicity at ³ 572 mg
m–2 day–1. In a population of patients with metastatic cancer, it was
often difficult to assign causality, but in certain patients there was
a clear temporal relationship to drug administration (Figure 1) and
spontaneous resolution in the absence of any suggestion of disease
progression. Data from these patients confirmed the relationship
between drug administration and liver function test abnormalities
which was self-limiting and not associated with any significant
clinical sequelae.
Nolatrexed pharmacokinetics
Pharmacokinetic data were available from 22 patients. Data were
available from 23 courses of treatment because nolatrexed was
administered at two successive dose levels in one patient.
Nolatrexed was measured in plasma 30–60 min after capsule
administration and at approximately 6 h (Table 3). There was no
evidence of accumulation over the 10-day period of dosing.
Median trough values, shown in Table 3, support the data of Rafi
et al (1998), which demonstrated that nolatrexed clearance is dose
dependent. Plasma concentrations of 3–11 mg ml–1 were achieved
in patients 30–60 min after dosing at the 429 mg m–2 day–1 dose
level with ‘trough’ values of 0.6–2.6 mg ml–1.
The 30–60 min concentration cannot be assumed to represent a
true peak value and therefore cannot be used for correlation with
the toxicities noted. When mean trough values were considered,
no correlation could be found with the recorded toxicities.
Plasma deoxyuridine (dUrd) concentrations
Data available from 12 out of 23 patients confirm that plasma
dUrd concentrations rise (median rise = 90% of baseline) after oral
administration of nolatrexed (Figure 2), as might be predicted by
the achievement of relevant plasma concentrations of nolatrexed.
The magnitude of the elevation of dUrd is similar to that seen after
the intravenous administration of nolatrexed (Rafi et al, 1998).
Data were only available in one out of six patients treated at the
maximum dose because five out of six first cycles of treatment
were not completed. Data were available from four out of nine
patients receiving 429 mg m–2 day–1, and in three out of four the
elevation in dUrd was > 75% compared with baseline. In this small
number of patients, it was not possible to identify any relationships
between change in dUrd and toxicity.
Anti-tumour activity
Ten out of 23 patients had evaluable disease, and, of these, seven
had progressive disease on treatment and three patients achieved
disease stabilization; 122 days (adenocarcinoma small intestine,
patient A), 219 days (gastric cancer, previous partial response with
5-FU, doxorubicin and mitomycin C, patient B) and 70 days
(NSCLC), measured from the start of nolatrexed. Patient A
received five cycles of nolatrexed and, on disease progression, was
918 DI Jodrell et al
British Journal of Cancer (1999) 79(5/6), 915–920 © Cancer Research Campaign 1999
700
600
500
400
300
200
100
0
70
60
50
40
30
20
10
0
01 02 03 04 05 06 0 9 0 80 70 100
Time (days)
ALT Bilirubin
PD
A
l
a
n
i
n
e
 
t
r
a
n
s
a
m
i
n
a
s
e
B
i
l
i
r
u
b
i
n
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
80
159
159
318
318
318
429
429
429
429 572
Thymitaq dose (m–2 day–1)
P
l
a
s
m
a
 
d
U
r
d
318
Pre nolatrexed Day 10
Table 3 Nolatrexed plasma concentrations. Patients sampled on days 1, 3
and 8. All doses and concentrations are expressed as nolatrexed-free base
Dose Time point Median Range
(mg m–2 day–1)( mg ml–1)( mg ml–1)
572 30–60 min 12.3 5.8–16.2
Trough 4.7 2.7–8.0
429 30–60 min 7.4 3.0–11.2
Trough 1.8 0.6–2.6
318 30–60 min 8.1 4.7–8.3
Trough 1.0 0.2–1.4
159 30–60 min 2.2 1.9–2.8
Trough 0.2 0.1–1.4
Figure 1 Changes in liver function tests (alanine transaminase and
bilirubin) after the administration of nolatrexed (day 0) in one patient. PD,
disease progression
Figure 2 Plasma deoxyuridine estimations before nolatrexed administration
and on day 10 in 12 patientstreated using 5-FU/folinic acid chemotherapy with further disease
stabilization. He survived 23 months after treatment with nola-
trexed. Patient B received six cycles of nolatrexed and remains
alive 19 months after treatment.
DISCUSSION
This paper describes a completed phase I trial of the novel TS
inhibitor, nolatrexed, administered orally over 10 days, repeated at
3-weekly intervals. The maximum tolerated dose of nolatrexed
administered using this schedule was 572 mg m–2 day–1 (143 mg
m–2 every 6 h). Nausea was the dose-limiting toxicity, causing
discontinuation of therapy in five out of eight cycles on days 4–8
at 572 mg m–2 day–1, despite prophylactic antiemetic therapy
including both dexamethasone and ondansetron. Nine patients
were treated at the lower dose level of 429 mg m–2 day–1 and three
out of nine patients experienced CTC grade 3 nausea. However, 17
out of 22 treatment courses were completed (with the co-
administration of prophylactic antiemetics) and this dose level
(429 mg m–2 day–1) could be considered for phase II testing of
nolatrexed administered for 10 days by mouth.
In comparison, in the 10-day intravenous infusion study using
nolatrexed reported by Creaven et al (1998), dose escalation to
716 mg m–2 day–1 was performed, but zero out of three patients
completed this dose level and two out of three developed grade 4
myelosuppression. A dose level of 572 mg m–2 day–1 was tolerated
with one out of four patients developing dose-limiting myelo-
supression, but concern was expressed at the high incidence of
thrombotic complications using the continuous infusion protocol.
When nolatrexed was administered by 5-day intravenous infusion
(Rafi et al, 1998), the maximum tolerated dose was 904 mg m–2
day–1 and the recommended phase II dose was 800 mg m–2 day–1.
The dose-limiting toxicity was neutropenia. Anti-tumour activity
was noted with one patient with metastatic colorectal cancer
achieving a partial response, lasting 3 months. Nausea and
vomiting was reported as mild to moderate, although ondansetron
was used in 9 out of 31 patients.
In our 10-day oral study, antiproliferative toxicities (neutropenia,
thrombocytopenia and stomatitis) were documented at dose levels
³ 318 mg m–2 day–1. CTC grade 1 thrombocytopenia (four out of
nine patients), CTC grade 2 neutropenia (one out of nine patients)
and CTC grade 2 stomatitis (two out of nine patients) were demon-
strated at 429 mg m–2 day–1.
Liver function test (LFT) abnormalities were noted in a proportion
of patients (CTC grade 3 ALT in 2 out of 19, CTC grade 3 bilirubin
in 5 out of 19 and CTC grade 4 bilirubin in 1 out of 19) receiving
doses ³ 318 mg m–2 day–1. Of the six patients with elevation of their
bilirubin levels, four had normal bilirubin levels at the start of treat-
ment and two were marginally elevated (18 and 17 mmol 1–1; upper
limit of normal, 16 mmol 1–1), but all six had normal ALT levels at the
onset of therapy. These LFT abnormalities were self-limiting and
there were no significant clinical sequelae. Transient LFT abnormal-
ities are reported with raltitrexed, a TS inhibitor in regular clinical use
[data sheet: raltitrexed (Zeneca)], and need not limit its usage.
Skin rashes were seen in eight patients and an additional five
patients noticed apparent photosensitivity. The rashes were more
prominent in sun-exposed areas. Skin toxicites are often identified
in patients receiving antimetabolite drugs [data sheets: reltitrexed
(Zeneca), methotrexate (Faulding), flurouracil (Faulding)].
A dose level of 429 mg m–2 day–1 might be considered appro-
priate for phase II testing, although prophylactic antiemetic
therapy would be required. The availability of 20 and 80 mg
capsules meant that patients were required to take three to five
capsules every 6 h. In patients who are experiencing nausea which
they associate with the treatment, this is a major undertaking and,
therefore, capsules containing larger quantities of nolatrexed (50
and 200 mg) could be produced, and it would be appropriate to re-
evaluate the higher doses tested in this study using any new formu-
lation before proceeding to formal phase II testing. An alternative
strategy would be the development of a sustained release formula-
tion and this is also being considered.
The pharmacokinetic studies demonstrate that the drug is
absorbed and plasma concentrations are achieved at 429 mg m–2
day–1 (³ 0.8 mg ml–1), which would be associated with anti-tumour
activity in vitro (Webber et al, 1996). It is intended that the limited
plasma concentration data collected in this study will be combined
with data from studies using different schedules and routes of
administration to develop a population pharmacokinetic model for
nolatrexed. The plasma concentrations achieved in this study
would be expected to result in inhibition of the target enzyme,
thymidylate synthase, and the elevation of plasma deoxyuridine
(dUrd) concentrations seen in these patients supports this.
In summary, it has been shown that nolatrexed can be adminis-
tered every 6 h for 10 days at doses sufficient to cause antiprolifer-
ative toxicities and which show evidence of thymidylate synthase
inhibition. The tolerable dose in this oral study is lower than the
tolerable dose determined using 10-day continuous intravenous
administration. The pharmaceutical preparation used in this oral
study was associated with dose-limiting nausea and vomiting,
which may be reduced by modification of the formulation and
such studies are ongoing. Nolatrexed has been shown to be an
active drug in the treatment of head and neck cancer and hepato-
cellular carcinoma (Clendeninn et al, 1996), and its clinical devel-
opment has now progressed to phase III trials. The necessity for
the administration of nolatrexed over a number of days and the
thrombotic complications associated with 10-day intravenous
infusions would suggest that oral administration would represent a
significant advantage.
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